CompletedNCT00132678

Long-acting risperidone to help prevent mood episodes in bipolarity

About this title

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Little Rock and 50 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateFebruary 2005

Recruitment status: Completed
Enrollment listed in the registry: 559
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Austria, India, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00132678
Official title: Show the full official title
A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension

Completed

Little Rock, United States · La Mesa, United States · National City, United States

49 more locations

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperdal Consta and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.